Is Merck & Co., Inc.'s (NYSE:MRK) CEO Pay Justified?

Ken Frazier became the CEO of Merck & Co., Inc. (NYSE:MRK) in 2011. This analysis aims first to contrast CEO compensation with other large companies. Next, we'll consider growth that the business demonstrates. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. The aim of all this is to consider the appropriateness of CEO pay levels.

Check out our latest analysis for Merck

Advertisement

How Does Ken Frazier's Compensation Compare With Similar Sized Companies?

At the time of writing, our data says that Merck & Co., Inc. has a market cap of US$197b, and reported total annual CEO compensation of US$28m for the year to December 2019. We note that's an increase of 32% above last year. While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$1.7m. Importantly, there may be performance hurdles relating to the non-salary component of the total compensation. When we examined a group of companies with market caps over US$8.0b, we found that their median CEO total compensation was US$12m. There aren't very many mega-cap companies, so we had to take a wide range to get a meaningful comparison figure.

Now let's take a look at the pay mix on an industry and company level to gain a better understanding of where Merck stands. On an industry level, roughly 24% of total compensation represents salary and 76% is other remuneration. Non-salary compensation represents a greater slice of the remuneration pie for Merck, in sharp contrast to the overall sector.

It would therefore appear that Merck & Co., Inc. pays Ken Frazier more than the median CEO remuneration at large companies, in the same market. However, this fact alone doesn't mean the remuneration is too high. We can better assess whether the pay is overly generous by looking into the underlying business performance. The graphic below shows how CEO compensation at Merck has changed from year to year.

NYSE:MRK CEO Compensation May 12th 2020
NYSE:MRK CEO Compensation May 12th 2020

Is Merck & Co., Inc. Growing?

Over the last three years Merck & Co., Inc. has seen earnings per share (EPS) move in a positive direction by an average of 50% per year (using a line of best fit). In the last year, its revenue is up 12%.

This shows that the company has improved itself over the last few years. Good news for shareholders. It's a real positive to see this sort of growth in a single year. That suggests a healthy and growing business. It could be important to check this free visual depiction of what analysts expect for the future.

Has Merck & Co., Inc. Been A Good Investment?

I think that the total shareholder return of 33%, over three years, would leave most Merck & Co., Inc. shareholders smiling. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.

In Summary...

We examined the amount Merck & Co., Inc. pays its CEO, and compared it to the amount paid by other large companies. Our data suggests that it pays above the median CEO pay within that group.

However, the earnings per share growth over three years is certainly impressive. On top of that, in the same period, returns to shareholders have been great. So, considering this good performance, the CEO compensation may be quite appropriate. On another note, we've spotted 1 warning sign for Merck that investors should look into moving forward.

Important note: Merck may not be the best stock to buy. You might find something better in this list of interesting companies with high ROE and low debt.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About NYSE:MRK

Merck

Operates as a healthcare company worldwide.

Reasonable growth potential with adequate balance sheet and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7063.2% undervalued
43 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9635.5% undervalued
47 users have followed this narrative
8 users have commented on this narrative
17 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0539.5% undervalued
45 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
TO
Tokyo
OKTA logo
Tokyo on Okta ·

Good foundation, but now it's all about the next steps

Fair Value:US$15121.8% undervalued
91 users have followed this narrative
7 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

RO
RockeTeller
IVR logo
RockeTeller on Investigator Silver ·

Investigator Silver, Leverage Exposed: $1/oz Move = $42M Cash for This ASX Developer

Fair Value:AU$2.3997.7% undervalued
15 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
TA
Talos
VOYG logo
Talos on Voyager Technologies ·

The "Landlord of Orbit" – A Deep Value Play Ahead of the Starlab Era

Fair Value:US$385.289.5% undervalued
17 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TA
Talos
AMD logo
Talos on Advanced Micro Devices ·

The "David vs. Goliath" AI Trade – Why Second Place is Worth Billions

Fair Value:US$907.3239.7% undervalued
37 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7445.3% undervalued
66 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1929.0% undervalued
51 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9721.9% undervalued
58 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative